Decalogue: Ten Ideas to Accelerate Patient Access & Therapeutic Understanding of Medicinal Cannabis
Features contributions from a diverse mix of experts, innovators and pioneers from industry, investment, academia and public policy.
The Centre for Medicinal Cannabis (CMC) was launched 3 years ago in December 2018. A month earlier new legislation came into effect which enabled UK doctors to legally prescribe medicinal cannabis for the first time.
Since then two cannabis based products have been approved for prescribing in the NHS by NICE, new clinics have been established to allow clinicians to prescribe in the private sector, a number of medicinal cannabis companies have listed on the London Stock Exchange and a suite of new startups have been granted commercial licences to grow high-THC cannabis.
So some progress but as the CMC report Left Behind: The scale of illegal cannabis use for medicinal intent in the UK found over 1.4 million British adults are currently accessing cannabis in the illicit market to treat a wide range of clinical conditions.
Fresh thinking is now required if we are to both increase patient access and clinical understanding of medicinal cannabis.
Decalogue is designed to provide novel, constructive ideas which provoke debate and action in political, public policy, medical and investment domains. Alongside a suite of practical but innovative propositions focused on smarter regulation the pamphlet provides illuminating insights from other countries and from social action in the UK to contextualise. Decalogue features contributions from a diverse mix of experts, innovators and pioneers from industry, investment, academia and public policy.
Decalogue Authors & Papers
1. Prioritising Clinical studies and regulatory reviews of CBPMs
Prof Trevor Jones, Chairman at e-Therapeutics Plc
Dr Parveen Bhatarah, Regulatory & Compliance Associate | The Centre for Medicinal Cannabis
2. Taking Forward the Key TIGRR recommendations - Moving licensing from Home Office to DHSC
Dr Andy Yates, Chief Scientific Officer | Artelo Biosciences,
Dr Parveen Bhatarah, Regulatory & Compliance Associate | The Centre for Medicinal Cannabis
Dr Paul Dickenson, Founder | SEDA Pharmaceuticals
Steve McConchie, CEO | Aptus Clinical
3. A New Case for Permitting Prescribing in Primary Care
Dr Daniel Couch, Medical Lead | The Centre for Medicinal Cannabis
4. What we have achieved in medicinal cannabis
Pierre van Weperen, Managing Director | Grow Group UK
5. A Risk-based Approach to Cannabis
Hari Guliani, Head of Columbia Care International
6. Equal Treatment - CBMP’s and Specials
Jonathan Hodgson, CEO | Rokshaw Laboratories
Pierre van Werpen, Managing Director | Grow Group UK
7. Can extending access to medicinal cannabis address health inequalities?
Dr Ayesha Mian, Medical Advisor | The Centre for Medicinal Cannabis
8. Policing illicit medicinal cannabis
Carly Barton, Founder | Cancard
9. Germany - Europe’s Cannabis Frontier
Alfredo Pascual, Investment Analyst | Seeds Innovations
10. Reforming the Proceeds of Crime Act
Alex Brookes, Senior Analyst | Cannaccord Genuity
Dylan Kennett | Senior Associate | DLA Piper